Marcie A. Goldstein

Davis Polk advised the underwriters in connection with a public offering of 6,900,000 shares of common stock of Revolution Medicines, Inc. at $26.00 per share (which includes the…

Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the $69 million follow-on offering of common stock of Magenta Therapeutics…

Davis Polk advised the underwriters in connection with a public offering of 6,666,667 shares of common stock of IDEAYA Biosciences, Inc. at $15.00 per share, for total gross proceeds of …

Davis Polk advised the underwriters in connection with the initial public offering of 51,750,000 units of Trebia Acquisition Corp., including 6,750,000 units purchased pursuant to the…

Davis Polk advised the representatives of the underwriters in connection with the $230 million initial public offering of 12,105,263 shares of common stock of Generation Bio Co., which…

Davis Polk advised the sales agent in connection with an SEC-registered at-the-market offering by Applied Therapeutics, Inc. of shares of its common stock for up to a maximum offering…

Davis Polk advised the sole underwriter in connection with an SEC-registered secondary offering of 10,000,000 shares of common stock of BrightView Holdings, Inc. by KKR BrightView…

Davis Polk advised the underwriters in connection with the $487 million SEC-registered initial public offering by Legend Biotech Corporation of 21,188,750 American Depositary Shares, each…

Davis Polk advised the representatives of the several underwriters, in connection with the $1.925 billion initial public offering of 77,000,000 shares of Class A common stock of Warner…

Davis Polk advised the representatives of the several underwriters, in connection with the initial public offering of 103,500,000 units of Foley Trasimene Acquisition Corp., including…